Market Closed -
Nyse
04:10:00 2024-04-29 pm EDT
|
5-day change
|
1st Jan Change
|
1.01
USD
|
-1.94%
|
|
-4.72%
|
-82.05%
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
25.28
|
23.07
|
41.2
|
51.91
|
12.36
|
14.46
|
Enterprise Value (EV)
1 |
5.193
|
5.784
|
24.46
|
25.44
|
1.557
|
11.3
|
P/E ratio
|
-0.99
x
|
-1.42
x
|
-0.96
x
|
-3.21
x
|
-0.89
x
|
-0.61
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
-
|
-
|
596,779,622
x
|
93,975,548
x
|
383,930,364
x
|
EV / Revenue
|
-
|
-
|
-
|
292,498,557
x
|
11,842,208
x
|
299,979,895
x
|
EV / EBITDA
|
-0.52
x
|
-0.37
x
|
-0.92
x
|
-1.62
x
|
-0.11
x
|
-0.54
x
|
EV / FCF
|
-0.9
x
|
-0.75
x
|
-1.58
x
|
-3.08
x
|
-0.15
x
|
-1.22
x
|
FCF Yield
|
-111%
|
-133%
|
-63.3%
|
-32.5%
|
-681%
|
-81.7%
|
Price to Book
|
1.71
x
|
2.25
x
|
4.26
x
|
2.18
x
|
1.12
x
|
11
x
|
Nbr of stocks (in thousands)
|
491
|
735
|
1,529
|
1,940
|
1,960
|
2,569
|
Reference price
2 |
51.53
|
31.38
|
26.94
|
26.76
|
6.306
|
5.626
|
Announcement Date
|
3/29/19
|
3/4/20
|
3/1/21
|
3/24/22
|
4/17/23
|
3/29/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
|
-
|
-
|
-
|
0.087
|
0.1315
|
0.0377
|
EBITDA
1 |
-9.965
|
-15.82
|
-26.59
|
-15.73
|
-14.38
|
-20.88
|
EBIT
1 |
-9.995
|
-15.88
|
-26.64
|
-15.77
|
-14.42
|
-20.9
|
Operating Margin
|
-
|
-
|
-
|
-18,131.88%
|
-10,964.61%
|
-55,519.89%
|
Earnings before Tax (EBT)
1 |
-9.914
|
-15.57
|
-26.43
|
-15.71
|
-14.29
|
-20.66
|
Net income
1 |
-9.914
|
-15.57
|
-26.43
|
-15.71
|
-14.29
|
-20.66
|
Net margin
|
-
|
-
|
-
|
-18,062.03%
|
-10,863.96%
|
-54,858.14%
|
EPS
2 |
-52.12
|
-22.09
|
-28.05
|
-8.348
|
-7.111
|
-9.182
|
Free Cash Flow
1 |
-5.786
|
-7.674
|
-15.49
|
-8.27
|
-10.61
|
-9.226
|
FCF margin
|
-
|
-
|
-
|
-9,507.43%
|
-8,065.25%
|
-24,503.94%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/29/19
|
3/4/20
|
3/1/21
|
3/24/22
|
4/17/23
|
3/29/24
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
---|
Net sales
1 |
-
|
0.087
|
0.0151
|
0.0304
|
0.086
|
-
|
0.017
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-4.394
|
-2.301
|
-6.055
|
-4.047
|
-3.954
|
-0.3604
|
-2.905
|
Operating Margin
|
-
|
-2,645.27%
|
-40,149.4%
|
-13,317.31%
|
-4,594.49%
|
-
|
-17,067.1%
|
Earnings before Tax (EBT)
1 |
-4.384
|
-2.293
|
-6.035
|
-4.033
|
-3.918
|
-0.3027
|
-2.845
|
Net income
1 |
-4.384
|
-2.293
|
-6.035
|
-4.033
|
-3.918
|
-0.3027
|
-2.845
|
Net margin
|
-
|
-2,635.45%
|
-40,022.48%
|
-13,269.79%
|
-4,552.75%
|
-
|
-16,714.69%
|
EPS
2 |
-2.400
|
-1.200
|
-3.000
|
-1.800
|
-1.800
|
-0.5400
|
-1.410
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
11/15/21
|
3/24/22
|
5/13/22
|
8/9/22
|
11/14/22
|
4/17/23
|
5/12/23
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
20.1
|
17.3
|
16.7
|
26.5
|
10.8
|
3.16
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-5.79
|
-7.67
|
-15.5
|
-8.27
|
-10.6
|
-9.23
|
ROE (net income / shareholders' equity)
|
-72.9%
|
-81.7%
|
-155%
|
-72.5%
|
-72.4%
|
-255%
|
ROA (Net income/ Total Assets)
|
-42.7%
|
-47.5%
|
-86.7%
|
-42%
|
-41.9%
|
-132%
|
Assets
1 |
23.22
|
32.78
|
30.5
|
37.38
|
34.08
|
15.59
|
Book Value Per Share
2 |
30.10
|
13.90
|
6.320
|
12.30
|
5.640
|
0.5100
|
Cash Flow per Share
2 |
41.20
|
23.80
|
11.50
|
14.10
|
5.640
|
1.130
|
Capex
1 |
0.12
|
0.03
|
-
|
0.04
|
0.13
|
-
|
Capex / Sales
|
-
|
-
|
-
|
50.44%
|
96.96%
|
-
|
Announcement Date
|
3/29/19
|
3/4/20
|
3/1/21
|
3/24/22
|
4/17/23
|
3/29/24
|
|
1st Jan change
|
Capi.
|
---|
| -82.05% | 4.62M | | -2.63% | 103B | | +1.62% | 95.28B | | +1.46% | 22.15B | | -16.67% | 21.02B | | -8.58% | 18.15B | | -38.74% | 16.73B | | -13.21% | 16.05B | | +5.41% | 13.68B | | +33.57% | 12.17B |
Bio Therapeutic Drugs
|